SPRYD4 and Alzheimer disease: Of these, only eQTLs for SPRYD4 colocalised with both a risk metabolite and its respective neuropsychiatric outcome: the ratio of histidine-to-glutamine (PP.H4 = 0.91) and AD (PP.H4 = 0.91).